Melekos M D
Department of Urology, University of Patras School of Medicine, Rio, Greece.
Urol Int. 1990;45(3):137-41. doi: 10.1159/000281695.
A controlled prospective study in 100 patients evaluated the efficacy of intravesical bacillus Calmette-Guérin (BCG) administration as prophylactic treatment on tumor recurrence and tumor progression rate after endoscopic resection of superficial transitional cell carcinoma of the bladder. There were 27 recurrences in 22 of 67 evaluable patients (33%) who received BCG, compared to 27 recurrences in 19 of 33 control patients (58%) (p less than 0.05). The mean follow-up periods for the tumor-free patients in the BCG and control groups were 29 and 30 months, respectively, while the mean times to tumor recurrences for the above groups were 13.36 +/- 6 and 9.94 +/- 5 months, respectively (p less than 0.05). The recurrence rates per 100 patient months for the BCG and control patients were 1.69 and 4.41 recurrences, respectively (p less than 0.05), while 7 patients of the BCG group showed recurrent tumors of higher stage or grade, compared to 13 of the controls (p less than 0.05). This study confirms that Pasteur strain BCG is safe and efficacious in the prevention of superficial bladder tumor recurrence and tumor progression.
一项针对100例患者的对照前瞻性研究评估了膀胱内灌注卡介苗（BCG）作为预防性治疗对膀胱浅表移行细胞癌内镜切除术后肿瘤复发和肿瘤进展率的疗效。在67例可评估的接受BCG治疗的患者中，有22例出现27次复发（33%），相比之下，33例对照组患者中有19例出现27次复发（58%）（p<0.05）。BCG组和对照组无瘤患者的平均随访期分别为29个月和30个月，而上述两组肿瘤复发的平均时间分别为13.36±6个月和9.94±5个月（p<0.05）。BCG组和对照组每100患者月的复发率分别为1.69次和4.41次（p<0.05），BCG组有7例患者出现更高分期或分级的复发肿瘤，而对照组有13例（p<0.05）。本研究证实，巴斯德菌株BCG在预防浅表性膀胱肿瘤复发和肿瘤进展方面是安全有效的。
